Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas.

A Phase I/II clinical trial was undertaken between January 29, 1987 and January 25, 1997 to assess the efficacy of (125)I-labeled monoclonal antibody 425 ((125)I-MAb 425) in controlling high-grade brain gliomas. A total of 180 patients diagnosed with glioblastoma multiforme (GBM) and astrocytoma with anaplastic foci (AAF) were administered (125)I-MAb 425 as an adjuvant treatment. All underwent initial surgery followed by postoperative external beam radiation therapy and a cumulative dose of 140 mCi of (125)I-MAb 425. Biodistribution of radioactivity after antibody administration showed increased uptake in brain tumor cells due to enhanced expression of epidermal growth factor receptors. A longer half-life of (125)I-MAb 425 in brain tumor cells compared to blood was observed. All patients were followed up for at least 5 years. Overall actuarial survival range for GBM and AAF patients showed 4-150 and 4-270 months, respectively. GBM and AAF patients under age 40 years with a Karnofsky performance status >70 had an actuarial median survival of 22.5 and 65 months, respectively. This adjuvant therapy demonstrates a significant increase in median survival and should be considered in the management of high-grade brain gliomas.

[1]  M. Waterfield,et al.  Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. , 1986, Cancer research.

[2]  S. Soong,et al.  The prognostic impact of prior low grade histology in patients with anaplastic gliomas , 1996, Neurology.

[3]  D. Qin,et al.  [Influence of radiation on the blood-brain barrier and optimum time of chemotherapy]. , 1990, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.

[4]  Brady Lw.  A new treatment for high grade gliomas of the brain. , 1998 .

[5]  N. Nomura,et al.  High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. , 1986, Cancer research.

[6]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[7]  W. Haseltine,et al.  Range of radiochemical damage to DNA with decay of iodine-125. , 1981, Science.

[8]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[9]  M. Herlyn,et al.  Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. , 1987, Cancer research.

[10]  I. Petersen,et al.  Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. , 1992, Journal of neurosurgery.

[11]  T. Kwok,et al.  Cell cycle dependence of epidermal growth factor induced radiosensitization. , 1992, International journal of radiation oncology, biology, physics.

[12]  Z. Steplewski,et al.  Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1a in human cancer cells. , 1989, Cancer research.

[13]  R. Class,et al.  Radioiodinated (I-125) Monoclonal Antibody 425 in the Treatment of High Grade Glioma Patients: Ten-Year Synopsis of a Novel Treatment , 2002, American journal of clinical oncology.

[14]  D. Nelson,et al.  Long‐Term Survival in Treated Anaplastic Astrocytomas: A Report of Combined RTOG/ECOG Studies , 1991, American journal of clinical oncology.

[15]  A. Alavi,et al.  Radioimmunodetection of human glioma xenografts by monoclonal antibody to epidermal growth factor receptor. , 1987, Cancer research.

[16]  H. Koprowski,et al.  Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. , 1992, International journal of radiation oncology, biology, physics.

[17]  T. Libermann,et al.  Expression of epidermal growth factor receptors in human brain tumors. , 1984, Cancer research.

[18]  C. Macleod,et al.  Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Ozanne,et al.  Human squamous cell lung cancers express increased epidermal growth factor receptors. , 1984, The Journal of clinical investigation.

[20]  K. Hofer,et al.  Radiotoxicity of intranuclear tritium, 125 iodine and 131 iodine. , 1971, Radiation research.

[21]  P. Echlin,et al.  Amplification and overexpression of the EGF receptor gene in primary human glioblastomas , 1985 .

[22]  Y. Imai,et al.  Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. , 1982, Cancer research.

[23]  M. Bennett,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS , 1985, The Lancet.

[24]  U. Rodeck,et al.  Radiotoxicity of 125I‐Labeled Monoclonal Antibody 425 Against Cancer Cells Containing Epidermal Growth Factor Receptor , 1992, American journal of clinical oncology.

[25]  G. Schultz,et al.  Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. , 1984, Cancer research.

[26]  M. Melamed,et al.  Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. , 1986, Cancer research.

[27]  R. Class,et al.  Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients , 2002 .

[28]  P. Nowell,et al.  Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma , 1985, Somatic cell and molecular genetics.

[29]  G. Sherbet,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER , 1985, The Lancet.